Table 4.
Absolute proportion in self sampling arm and contrasts between self sampling and control arms
| Parameter | No of studies* | Absolute proportion self sampling % (95% CI) | No of studies† | Relative proportion (95% CI) | Proportion difference % (95% CI) |
|---|---|---|---|---|---|
| Unsatisfactory sample | 16 | 0.7 (0.4 to 1.0) | NA | NA | NA |
| Test positivity‡ | 22 | 11.1 (9.8 to 12.4) | NA | NA | NA |
| Adherence to follow-up | 20 | 80.6 (67.0 to 91.5) | 10 | 0.91 (0.80 to 1.04) | −4.8 (−13.1 to 3.5) |
| CIN2+ detection per thousand invited §¶ | 18 | 2.6 (1.4 to 4.1) | 14 | 2.28 (1.44 to 3.61) | 1.6 (0.1 to 3.1) |
| CIN2+ detection per thousand screened**¶ | 18 | 9.8 (7.1 to 13.0) | 14 | 1.13 (0.63 to 2.04) | 2.9 (−1.7 to 7.5) |
NA=Not available; CIN2+=cervical intraepithelial neoplasia grade 2 or worse.
*
Reporting the parameter in both the self sampling and control arms.
†
Reporting the parameter in the self sampling arm.
‡
Of high-risk human papillomavirus (hrHPV) assay in the self sampling arm (per protocol).
§
Depends on participation, adherence to follow-up, prevalence of disease among participants, and sensitivity of tests (screening and follow-up).
¶
Restricted to data where a Pap smear was taken in the control arm.
**
Depends on adherence to follow-up, prevalence of disease among participants and sensitivity of tests (screening and follow-up).